Log In
Wednesday 21st March 2018

New schizophrenia drug

4th September 2007

Scientists have reported that the first human trials of a new schizophrenia drug has yielded promising results.

Patients treated with “LY2140023? showed improvements in symptoms and few side effects and experts now say that the Nature Medicine study, by drug firm Eli Lilly, should prompt further trials.

The experimental drug targets glutamate receptors in the brain rather than dopamine. Mental health charity Rethink welcomed the results and called for higher levels of investment from the pharmaceutical industry in research in drug treatments for schizophrenia that reduce side effects whilst still being effective.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based applications for healthcare
© Mayden Foundation 2018